TICTalk Series 2 Banner

Webinar 2: Let's look at our patients!

Document ID: PC-SSK-101630

11/08/2022

Author: Boehringer Ingelheim

  • Please click the timestamp to watch topic you are interested in.
  • - 00:00:00 Opening and introduction to the panelists
  • - 00:03:09 In terms of disease/health literacy, where are our HF patients? Are we doing enough to educate them
  • - 00:15:36 Intensification of HF therapy is often met with resistance from patients. What are the reasons for this?
  • - 00:28:29 Characteristics of HF patients determine therapy utilization. What are these characteristics and how do they contribute to treatment inertia?
  • - 00:46:00 How applicable is SGLT2i/empagliflozin as an early HF therapy among these various patient profiles?
  • - 01:02:54 Which attributes of SGLT2i/empagliflozin matter most to patients and hence should be part of the discussion with them?

123,000
Views

100k 340

PC-SSK-101630
Production date: Aug 2022